XML 22 R6.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2023
Dec. 31, 2022
Jun. 30, 2022
Mar. 31, 2022
Dec. 31, 2022
Operating Activities          
Net loss $ (7,432) $ (27,468) $ (6,557) $ (8,906)  
Net income from discontinued operations     (226)  
Net loss from continuing operations (7,432)     (9,132)  
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:          
Depreciation expense 632     4,328  
Amortization expense 2,369     2,369  
Stock-based compensation 847     927  
Consultant stock compensation 32     28  
Deferred income taxes (547)     (547)  
Impairment on fixed assets 209      
Amortization of operating lease asset 56     50  
Gain on debt revaluation, net (473)      
Amortization on deferred financing costs and discount on notes 501     2,447  
Loss on sale of fixed assets 78      
Changes in operating assets and liabilities:          
Accounts receivable 41     206  
Prepaid expenses and other current assets (26)     (594)  
Other long-term assets (300)     59  
Accounts payable 1,368     1,405  
Deferred revenue (453)     (9)  
Operating lease liabilities (54)     (49)  
Other liabilities 104      
Accrued liabilities (5)     (687)  
Net cash (used in) provided by operating activities (3,053)     801  
Net cash provided by operating activities- discontinued operations     510  
Investing Activities          
Purchases of property, plant, and equipment (860)     (25,438)  
Purchases of intangible assets (24)     (40)  
Proceeds from disposal on property, plant, and equipment 249      
Deposits of equipment, net 200     (2,590)  
Net cash used in investing activities (435)     (28,068)  
Net cash provided by (used in) investing activities- discontinued operations      
Financing Activities          
Proceeds from preferred offerings     1,170  
Proceeds from common stock securities purchase agreement offering 41      
Proceeds from notes and debt issuance 900     19,767  
Costs of preferred offering     (155)  
Costs of common stock securities purchase agreement offering (4)      
Costs of notes and short-term debt issuance     (465)  
Cash dividend distribution on preferred stock     (749)  
Payments on NYDIG loans and line of credit (215)     (980)  
Contributions from non-controlling interest 5,991      
Proceeds from common stock warrant exercises     738  
Net cash provided by financing activities 6,713     19,326  
Increase (decrease) in cash & restricted cash-continuing operations 3,225     (7,941)  
Increase in cash & restricted cash- discontinued operations     510  
Cash & restricted cash – beginning of period 1,821   $ 2,827 10,258 $ 10,258
Cash & restricted cash – end of period 5,046 $ 1,821   2,827 $ 1,821
Supplemental Disclosure of Cash Flow Information          
Noncash equipment financing     4,620  
Interest paid on NYDIG loans and line of credit 6     345  
Noncash disposal of NYDIG collateralized equipment 3,388      
Notes converted to common stock 1,394     1,342  
Warrant consideration in relation to promissory notes and convertible notes     2,257  
Promissory note and interest conversion to common shares 401      
Registration fees in prepaids and accounts payable     (58)  
Noncash non-controlling interest contributions 2,767      
Series B preferred dividend in accrued expense (131)      
Noncash activity right-of-use assets obtained in exchange for lease obligations $ 397